Compare Cassava Sciences Inc (FLNA) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sunrun Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Sunrun Inc trades at $12.21 (market cap $3.05B). The key difference: Sunrun Inc is far larger — about 57.4× Cassava Sciences Inc's market cap, and Sunrun Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | RUN | |
|---|---|---|
Market Cap | $53.14M | $3.05B |
Sector | Health | Technology |
52-Week High | $4.64 | $21.41 |
52-Week Low | $1.09 | $9.07 |
Enterprise Value | -$33.43M | $17.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Sunrun (RUN) trades at $12.13, down 5.09% over 24 hours, with a bearish technical signal from moving averages. The company shows strong profitability with a 17.88% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a major partnership with Tesla and Renew Home to create a 16-gigawatt virtual power plant, positioning the company to capitalize on AI data center power demand.
The outlook is mixed; analyst consensus is bullish with a $16.27 price target, but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Upside depends on successful execution of new initiatives and improved cash generation, while volatility may persist amid market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
